Fig. 2

Famitinib facilitates PD-1 blockade to enhance antitumor immunity in a safe manner in vivo. A Study design and tumor growth curve in each treatment group. (n = 10 per group). B-C Tumor weight on the final day and mouse weight during treatment of each group as described above. D Proportion of CD8⁺ T cells among CD45⁺ cells and perforin⁺ cells among CD8⁺ T cells as assessed by flow cytometry. E Granzyme B and perforin expression as quantified by immunohistochemistry. F-G CD8⁺ and PD-L1⁺ cells as quantified by immunohistochemistry. Representative images of CD8 and PD-L1 staining are shown, with the mean cell number per HPF (800X) indicated. HPF, high-power field. Scale bars, 100 μm